MarketPulse

GLP-1 treatments

2 articles
BenzingaBenzinga··Vandana Singh

GoodRx Surges on Wegovy HD Expansion, Tapping $399/Month Self-Pay Obesity Market

GoodRx shares rose 2.69% as the platform expands access to Novo Nordisk's Wegovy HD at $399/month, capitalizing on the surging self-pay GLP-1 obesity treatment market.
LLYNVOGDRXobesity treatmentGLP-1 treatments
GlobeNewswire Inc.GlobeNewswire Inc.··Novo Nordisk

Novo Nordisk Invests €432M in Irish Plant to Boost GLP-1 Drug Output

Novo Nordisk invests €432M in Irish manufacturing expansion to boost oral GLP-1 drug production capacity, targeting completion by 2028.
NVOmanufacturing expansioninvestment